ASCO GI 2023 | Cabozantinib in patients with HCC refractory to checkpoint inhibitors

Whilst cabozantinib is approved in patients with hepatocellular carcinoma (HCC) who have progressed on sorafenib, its efficacy in patients who progress on immunotherapy has not been assessed. Stephen Lam Chan, MBBS, Chinese University of Hong Kong, Hong Kong, China, discusses findings from a Phase II trial (NCT04588051) of cabozantinib in patients with HCC who have progressed on checkpoint inhibitors. A median PFS of 4.1 months was reported and overall survival was better in patients who previously received atezolizumab and bevacizumab. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.